US FDA approves AstraZeneca’s new breast cancer pill Etcamah: Dosage, high risk and side effects — All you need to know

Camizestrant Receives FDA Accelerated Approval, Opening a New Front in Advanced Breast Cancer Therapy

Theindiapostdaily.com – The US Food and Drug Administration granted accelerated approval on Friday to a next-generation oral breast cancer agent developed by AstraZeneca Plc, marking a significant expansion of therapeutic options for adults facing locally advanced or metastatic disease. The compound, designated camizestrant and marketed under the brand name ETCAMAH®, targets a specific genetic vulnerability that emerges in a substantial subset of patients during endocrine-based treatment courses.

For women whose tumours have spread beyond the breast or developed resistance to standard hormonal therapies, this approval represents a meaningful shift in the treatment landscape. Rather than waiting for overt clinical or radiographic deterioration before altering strategy, clinicians now have a mechanism to intervene at an earlier inflection point in the disease trajectory.

How the Drug Functions

ETCAMAH operates as a potent, next-generation oral selective estrogen receptor degrader (SERD) combined with complete estrogen receptor antagonism. By dismantling the receptor machinery that estrogen uses to drive malignant cell proliferation, the agent effectively starves hormone-sensitive tumour cells of their growth signal. AstraZeneca’s clinical data demonstrated that the compound can postpone disease progression by more than six months in the studied population.

The medication is not administered as monotherapy. It is indicated exclusively in combination with agents from the CDK4/6 inhibitor class — specifically palbociclib, ribociclib, or abemaciclib — in patients whose tumours harbour an emergent ESR1 mutation. Before initiating therapy, patients must undergo an FDA-authorised companion test confirming the presence of this mutation.

The Evidence Base: SERENA-6

The approval rests on data from the pivotal SERENA-6 Phase III trial, whose primary results were presented at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The New England Journal of Medicine. The trial demonstrated that pairing camizestrant with a CDK4/6 inhibitor reduced the composite risk of disease progression or death by 56 percent among patients carrying an emergent ESR1 tumour mutation.

“Approval [was] based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation,” AstraZeneca said.

Notably, the FDA’s Oncology Drugs Advisory Committee had voted against the medicine earlier in the year, concluding it lacked a “meaningful benefit” for patients. The agency’s final decision, however, overruled that committee recommendation, affirming that the drug provides women with an additional avenue for managing their disease.

Dosage and Administration

The recommended daily dose of ETCAMAH, when co-administered with a CDK4/6 inhibitor, is 75 mg taken orally once per day. The tablets are intended for oral ingestion and require a valid prescription. Treatment should be initiated and overseen by a physician experienced in oncologic pharmacotherapy.

Per guidance from the European Medicines Agency, therapy continues for as long as the patient derives clinical benefit or until side effects become unacceptable. There is no fixed duration; ongoing assessment guides continuation decisions.

Risks and Safety Considerations

Pregnancy represents a major hazard. AstraZeneca cautioned that, based on animal findings and the drug’s mechanism of action, ETCAMAH can cause fetal harm when given to a pregnant woman. Women of reproductive potential should be counselled on this risk before starting therapy.

“Based on findings in animals and the mechanism of action, ETCAMAH can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus,” the company said.

Lactation is also contraindicated during treatment and for one week following the final dose, given the potential for drug transfer into breast milk.

Adverse Effects Profile

In combination with a CDK4/6 inhibitor, the most frequently observed adverse events — potentially affecting more than one in ten patients — include neutropenia, visual disturbances (notably photopsia, perceived as flashes of light within the visual field), infections, diarrhoea, nausea, anaemia, fatigue, bradycardia, and leucopenia. Among these, visual effects and bradycardia were identified as signals specifically attributable to camizestrant rather than to the companion CDK4/6 inhibitor.

More serious adverse events, though less common, warrant monitoring. Infections and fever emerged as the most frequent serious complications, each with a potential incidence approaching one in ten patients.

Global Footprint and Clinical Context

ETCAMAH already holds regulatory approval in more than thirty countries worldwide, including the European Union, Japan, Canada, and the United Kingdom, all grounded in the same SERENA-6 dataset. The US approval thus completes a major regulatory milestone for a drug that has been under development for several years.

The clinical relevance of targeting emergent ESR1 mutations is substantial. Approximately one in three patients with this form of advanced breast cancer develop such mutations before overt disease progression occurs. By identifying these patients through companion diagnostics and intervening with a SERD-based combination, oncologists can redirect therapy before irreversible tumour burden accumulates.

“The combination provides an important new option for the one in three patients with this form of advanced breast cancer whose tumors develop ESR1 mutations before clinical or radiographic disease progression,” said Kevin Kalinsky, MD, MS, FASCO, Division Director of Medical Oncology at the Winship Cancer Institute of Emory University and an investigator on the trial.

For patients navigating the complex landscape of advanced breast cancer management, the availability of ETCAMAH adds a precision-oriented tool to an already evolving therapeutic arsenal, underscoring the growing role of genomic biomarkers in guiding hormonal therapy decisions.